Friday, 24 March 2017

Targeting Monocytes with TLR7 Ligands as a Novel Opportunity in Immuno- Oncology

Monocytes

Cancer immunotherapy has for the last decade been one of the fastest developing therapeutic areas in oncology with promising clinical benefits, supporting a role of immunotherapy as a cornerstone in future cancer treatment in combination with existing treatments.

Treatment of early stage cancers today is very efficient due to refined surgery, chemotherapy, radiation and use of therapeutic antibodies, but a large group of patients in particular with late stage and metastatic disease have poor prognosis due to lack of efficient treatment options.

Thus, there is an urgent need to develop new technologies to provide more efficient treatment of late stage cancers, focused towards cure of these patients.

No comments:

Post a Comment